Models of Inflammation: Carrageenan Air Pouch

Duarte, Djane B.; Vasko, Michael R.; Fehrenbacher, Jill C.

doi:10.1002/0471141755.ph0506s56

Cited by 64 publications

(54 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The air pouch model is an established model for preclinical anti‐inflammatory drug efficiency studies. The air pouch mimics the synovial cavity and, when challenged with carrageenan (CA), provides a localized sterile inflammatory environment suitable to study PGs (Duarte, Vasko, & Fehrenbacher, ). All animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altma, ) and with the recommendations made by the British Journal of Pharmacology.…”

Section: Methodsmentioning

confidence: 99%

Biological characterization of new inhibitors of microsomal PGE synthase‐1 in preclinical models of inflammation and vascular tone

Larsson

Steinmetz

Bergqvist

et al. 2019

British J Pharmacology

View full text Add to dashboard Cite

Background and Purpose: Microsomal PGE synthase-1 (mPGES-1), the inducible synthase that catalyses the terminal step in PGE 2 biosynthesis, is of high interest as therapeutic target to treat inflammation. Inhibition of mPGES-1 is suggested to be safer than traditional NSAIDs, and recent data demonstrate anti-constrictive effects on vascular tone, indicating new therapeutic opportunities. However, there is a lack of potent mPGES-1 inhibitors lacking interspecies differences for conducting in vivo studies in relevant preclinical disease models.Experimental Approach: Potency was determined based on the reduction of PGE 2 formation in recombinant enzyme assays, cellular assay, human whole blood assay, and air pouch mouse model. Anti-inflammatory properties were assessed by acute paw swelling in a paw oedema rat model. Effect on vascular tone was determined with human ex vivo wire myography. Key Results:We report five new mPGES-1 inhibitors (named 934, 117, 118, 322, and 323) that selectively inhibit recombinant human and rat mPGES-1 with IC 50 values of 10-29 and 67-250 nM respectively. The compounds inhibited PGE 2 production in a cellular assay (IC 50 values 0.15-0.82 μM) and in a human whole blood assay (IC 50 values 3.3-8.7 μM). Moreover, the compounds blocked PGE 2 formation in an air pouch mouse model and reduced acute paw swelling in a paw oedema rat model. Human ex vivo wire myography analysis showed reduced adrenergic vasoconstriction after incubation with the compounds. Conclusion and Implications:These mPGES-1 inhibitors can be used as refined tools in further investigations of the role of mPGES-1 in inflammation and microvascular disease.

show abstract

Section: Methodsmentioning

confidence: 99%

Biological characterization of new inhibitors of microsomal PGE synthase‐1 in preclinical models of inflammation and vascular tone

Larsson

Steinmetz

Bergqvist

et al. 2019

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…i-Bodies Block Cell Recruitment in a Mouse in Vivo Modeli-Body efficacy in a murine in vivo study was performed by examining whether the i-bodies could antagonize cell recruitment in an "air pouch" model (58). In this study, the vehicleonly control showed extensive leukocyte migration into the air pouch in response to the presence of CXCL12 (Fig.…”

Section: Am3-114 Am3-523 and Am4-272 Recognize Overlapping But Distmentioning

confidence: 99%

i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4

Griffiths¹,

Dolezal

Cao

et al. 2016

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…Afterward, drug treatment is continued daily for 13 days. The foot size and body weights of the rats are measured appropriately [41].…”

Section: Adjuvant-induced Arthritismentioning

confidence: 99%

“…Secondary lesions involve the inflammation of the non-injected sites and a decrease in animal weight that occurs after 11-12 days due to immune response. The arthritic index was determined as the sum of the scores [41].…”

Section: Adjuvant-induced Arthritismentioning

confidence: 99%

In vitro and In vivo Models for Anti-inflammation: An Evaluative Review

Eze

Uzor

Peter

et al. 2019

INNOSC Theranostics and Pharmacological Sciences

View full text Add to dashboard Cite

Anti-inflammatory activity study involves developing a model that mimics, or provokes the production or release of, the biochemical mediators of inflammation, and monitoring the response of these biochemicals to the test drugs. This report constitutes an updated review of the in vitro and in vivo study models for assessing anti-inflammatory activity in plant extracts and synthetic drugs. The materials, instrumentation, and methods involved, as well as the mechanism of anti-inflammatory activity tested in each model, are extensively described. The merits and limitations of each method have also been discussed. A comparative assessment of the in vivo animal models vis-à-vis, the in vitro enzyme models have been made to assist scientists and researchers in the choice of assay method in terms of sensitivity, reliability, duration of test, ethical, and cost considerations.

show abstract

Models of Inflammation: Carrageenan Air Pouch

Cited by 64 publications

References 23 publications

Biological characterization of new inhibitors of microsomal PGE synthase‐1 in preclinical models of inflammation and vascular tone

Biological characterization of new inhibitors of microsomal PGE synthase‐1 in preclinical models of inflammation and vascular tone

i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4

In vitro and In vivo Models for Anti-inflammation: An Evaluative Review

Contact Info

Product

Resources

About